
Optimal Therapy for Genotype non-1 in Asia Pacific?

Dr Saeed Hamid Professor & Chair Department of Medicine Aga Khan University, Karachi



A systematic review of HCV epidemiology in Asia



Sievert, Liver Int 2011

1>3>2>4>6

Distribution Of HCV Genotypes in Pakistan

Genotype	Frequency	Percentage
1a	24	2.98
1b	29	3.60
2	12	1.49
3a	642	79.65
3b	66	8.19
4h, 4k	5	0.62
5a, 6a	15	1.86
10a	4	0.5
Non-typeable	9	1.12

N= 806

Moatter, Hamid et al, Intl. J. Inf. Dis. 2002

Distribution Of HCV Genotypes in Pakistan

Genotype	Frequency	Percentage
1a	24	2.98
1b	29	3.60
2	12 ult	<mark>0</mark> 2.49
3a	642 diffienot	79.65
3b	66 10 at	8.19
4h, 4k	5	0.62
5a, 6a	15	1.86
10a	4	0.5
Non-typeable	9	1.12

N= 806


Moatter, Hamid et al, Intl. J. Inf. Dis. 2002

Regional Distribution of *IL28B* rs12979860 CC Genotype



Thomas DL, et al. Nature. 2009;461:798-801.

The World based on Gross National Income & Public Health Spending



www.worldmapper


National Health Insurance system (Asia-Pacific region)

• Australia, Japan, New Zealand, China, Mongolia, Philippine, Vietnam, Korea, Taiwan

Countries with fully	Countries with partially
developed systems of social	developed systems of social
security	security
Australia, Japan, New Zealand	China, Mongolia, Philippines, Vietnam, Korea, Taiwan, Thailand


Source: ILO (2013). Social Security in the Asia and Pacific Region - An Overview. Global Extension of Social Security accessed on 3/20/2013 from: http://www.social-protection.org/gimi/gess/ShowRegionProfile.do?rid=11

Sources of health-care financing in selected Asia-Pacific countries, 2004




Note: Countries are listed in descending order of reliance on public financing (general revenue plus social insurance). Source: WHO (2007).

Proportion of people living on US 10\$ Purchasing Power Parity



www.woldmapper

Access to essential and affordable medicines : Use of traditionals and generics



www.worldmappers

APASL consensus statements and management algorithms for hepatitis C virus infection

Masao Omata · Tatsuo Kanda · Ming-Lung Yu · Osamu Yokosuka · Seng-Gee Lim · Wasim Jafri · Ryosuke Tateishi · Saeed S. Hamid · Wan-Long Chuang · Anuchit Chutaputti · Lai Wei · Jose Sollano · Shiv Kumar Sarin · Jia-Horng Kao · Geoffrey W. McCaughan

Hepatol Int (2012) 6:409–435

• Patients with HCV genotype 2 and 3 can be treated regardless of the stage of the disease (III).

In chronic HCV G/T 2 / 3 infection, the following apply: (I)

- Treatment with <u>either conventional interferon</u> alfa plus ribavirin <u>or peg-IFN alfa with or without ribavirin</u> for 24 weeks is recommended
- Peg-IFN plus ribavirin might be more effective in patients with cirrhosis.
- There is some evidence that shortening duration of therapy to 16 weeks in HCV genotype 2 infection provides equal SVR to 24 weeks treatment.

Response to Peg-interferon + Ribavirin for Chronic HCV in Asia

Patient population	Treatment regimen	Asian studies			
		Country	Reference	SVR rate	
Genotype 1:	PegIFN plus SD RBV for 48 weeks	China	Yu et al.67	44%	
		Japan	Kuboki et al.46	61%	
		Korea	Lee et al.56	70%	
		Taiwan	Liu <i>et al.</i> 60	76%	
		Taiwan	Liu et al.59	77%	
		Taiwan	Yu et al.61	79%	
Genotype 1, LVL, and RVR	PegIFN plus SD RBV for 24 weeks	Taiwan	Liu et al.60	94%	
1274 IS IS	T. 2	Taiwan	Yu et al.61	96%	
Genotype 2/3	PegIFN plus LD RBV for 24 weeks	China	Yu et al.67	75%	
		Taiwan	Liu et al.107	84%	
		Korea	Lee et al.56	94%	
	PegIFN plus SD RBV for 24 weeks	Taiwan	Yu et al.63	95%	
Genotype 2/3 and RVR	PegIFN plus SD RBV for 16 weeks	Taiwan	Yu et al.63	100%	
Genotype 4	PegIFN plus SD RBV for 48 weeks	Kuwait	Hasan <i>et al.</i> 53	68%	
Genotype 6	PegIFN plus SD RBV for 48 weeks	Hong Kong	Fung et al.15	86%	

LD RBV, lower dose of ribavirin, 800 mg/day; LVL, low baseline viral loads; PegIFN, peginterferon; RVR, rapid virological response; SD RBV, standard dose of ribavirin, 1000–1200 mg/day; SVR, sustained virological response.


Ming-Lung Yu, Journal of Gastroenterology and Hepatology 24 (2009)

Genotype 2 and 3 Short Term Treatment

	n	Treatment	Treatment Duration	RVR	SVR
Von Wagner	153	Peg-IFN alpha-2a and RBV 800- 1200	16 wks vs 24 wks	46%	16 wks: <mark>82%</mark> 24 wks: <mark>80%</mark>
Dalgard	122	Peg-IFN alpha-2b and RBV 800- 1400	14 wks vs 24 wks	78%	14 wks: <mark>90%</mark> 24 wks: <mark>56%</mark> (if no RVR)
Mangia	283	Peg-IFN alpha-2b and RBV 1000- 1200	12 wks vs 24 wks	62%	12 wks: <mark>85%</mark> 24 wks: <mark>64%</mark>

Shorter Treatment in Genotype 2/3 Patients Achieving RVR

- PegIFN alfa-2b + weight-based RBV
 - 14 weeks for patients with RVR; 24 weeks for patients without RVR



Dalgard O, et al. Hepatology. 2004;40:1260-1265.

Short Vs Standard Course Conventional Interferon Treatment in Patients with Genotype 3 Chronic HCV Infection. (STAR TRIAL: NCT 00502970)




Fig 2: The primary outcome measures i.e. SVR in the 24 vs. 16 weeks treatment (ITT analysis). Reported p-values are one-sided.

Short treatment in HCV Genotype 2 or 3

1469 treatment naïve patients with GT2 or 3, elevated ALT, HCV RNA >600 IU/mL, and compensated disease

Peg-IFN α -2a 180 μ g/wk + RBV 800 mg/d

Randomized



P<0.001

Treated x 24 wk

Treated x 16 wk


SVR

65%

"The decline in SVR associated with the shorter duration of therapy was the result of a higher relapse rate."

Shiffman ML, N Engl J Med 2007;357:124-134.

Racial differences in SVRs for Peg IFN + Riba therapy



Missiha S, C. Am. J. Gastroenterol. 2007; 102: 2181–8.


Roulot D, J. Viral Hepat. 2007; 14: 460–7. ¹⁷

HCV: Response to treatment at AKU

- Genotype-3 is found in 708/805 (87.8%) patients.
- The SVR to combination therapy (Interferon + Ribavirin) was achieved in 130/208 (62.5%)
- Patients of <35 years of age showed an SVR in 72%.
- The maximum SVR was achieved in patients aged 15-30 years (27/33, 81.8%)


Mumtaz et al, Saudi Med J 2008

IL28B Polymorphism and response to treatment in GT 2/3




Mangia, Gastro 2010

The "Accordion" Effect in HCV Therapy The Earlier HCV RNA Clears, The Shorter The Treatment Required




Sofosbuvir in Patients With GT2/3 HCV

 Interim analysis of nonrandomized phase II study with SOF (nucleoside polymerase inhibitor) ± GS-5885 (NS5A inhibitor)



Gane EJ, et al. AASLD 2012.

Polymerase Inhibitors Efficacy in Non–GT 1 Patients



1. Gane EJ, et al. AASLD 2012. Abstract 229. 2. Sulkowski M, et al. AASLD 2012. Abstract LB-2. 3. Hassanein T, et al. AASLD 2012. Abstract 230. 4. Hezode C, et al. AASLD 2012. Abstract 760.

Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection

FISSION:

- Sofosbuvir plus ribavirin in patients with HCV genotype 2 or 3 infection.
- 12 weeks of sofosbuvir plus ribavirin or 24 weeks of peginterferon alfa-2a plus ribavirin.
- SVR of 56% in GT 3 for Sof+Rib vs 63% for Peg+Riba
- SVR in patients with cirrhosis 47% for sofosbuvir + ribavirin vs 38% for peginterferon—ribavirin.
- Possible that response rates in patients with genotype 3 infection can be improved by adding peginterferon to sofosbuvir and ribavirin or by extending the duration of treatment with sofosbuvir and ribavirin.

Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options


POSITRON:

- 12 weeks of Sofosbuvir + Ribavirin vs placebo in patients who had previously discontinued interferon therapy.
- SVR 12= 61% for GT 3, 21% in cirrhotics

FUSION:

- Non-responders to prior PEG-IFN+Riba
- 12 or 16 weeks of Sofosbuvir + Ribavirin
- SVR 12= 30% and 62% respectively, among patients with HCV genotype 3 infection

VALENCE: Sofosbuvir/RBV for 24 Weeks in Patients Infected With Genotype 3 HCV



*11 additional patients with genotype 3 completed treatment before the protocol was amended. These patients were included with genotype 2 patients for safety analysis and analyzed separately for efficacy.



*RBV dosing by baseline weight: 1000 mg/day if < 75 kg or 1200 mg/day if ≥ 75 kg.</p>

VALENCE: Main Findings

- High overall SVR12 rates in both arms
 - 12-week treatment for genotype 2 HCV: 93% (68/73)
 - 24-week treatment for genotype 3 HCV: 85% (212/250)
- High SVR12 rates in patients with genotype 2 HCV regardless of previous treatment status and cirrhosis status (88-100%)
- SVR12 rates in genotype 3 HCV
 - Naive, non-cirrhotic: 94% (86/92)
 - Naive, cirrhotic: 92% (12/13)
 - Experienced, non-cirrhotic: 87% (87/100)
 - Experienced, cirrhotic: 60% (27/45)
- Sofosbuvir/RBV for 12 or 24 weeks was safe, well tolerated

Economic Burden of the HCV Epidemic

- Few countries have conducted studies to estimate HCV-related costs
 - Most studies have unreliable estimates
- In the US, total medical costs from HCV infection expected to increase from \$30 billion in 2009 to > \$85 billion in 2024
 - Estimate based on pegIFN/RBV treatment; potential impact of DAAs not reflected


The Role of Distributive Justice

- With expected high demands for DAA based all oral therapy, how will providers decide who gets treated first?
 - First-come, first-served approach?
 - Need-based allocation system?
- Distributive justice principle
 - Fair, equitable, and appropriate distribution of limited resources
 - Must balance equality with relative medical need when applying principle to scarce medical resource

Possible Solutions for Medication access: The HIV Paradigm

- Government purchases either directly or though UN support
- Drug supplied to "Certified Centers" in public and private sector that are accredited for treatment
- Drug is not available in market pharmacies: e.g. Rwanda

Lessons from the HIV World



Lessons for the HCV World

Even highly efficacious treatments are don't help if they aren't given



2001

Year

100

80-


60

40

201

1992

Individual SVR (%)



20

0

1992

Thomas Lancet 2010

2018

B Progress in eradication of chronic hepatitis C from the world if HCV

2001

Year

2018

Conclusions

- HCV genotype 3 is the predominant genotype after 1 in Asia.
- Interferon + Ribavirin combination therapy remains the mainstay of treatment of non-1 Genotype infection in Asia.
- HCV 3 responds heterogeneously to IFN/RIB therefore treatment has to be individualized.
- Well selected HCV 3 show excellent IFN responsiveness
- HCV 3 infection is likely to be the first to witness all oral DAA therapies.
- When that happens, much of Asia-Pacific will struggle with the cost of therapy.
- This however is also an opportunity to make a real difference to control HCV infection in this region.

APASL STC on HCV Pakistan, October 17-19, 2014

